Sanigen세니젠

Sanigen remains loss-making, with revenue shrinking and large operating losses through the first half of 2026.

Sanigen, a Korean food safety testing and sterilization company listed on KOSDAQ since late 2023, reported trailing revenue of ₩6.2B against an operating loss of ₩4.0B for the twelve months to H1 2026. Revenue has fallen from ₩20.2B in 2023 to ₩15.4B in 2025, and losses have been large each year. The company holds ₩6.4B in cash and no borrowings, but free cash flow is negative.

What stands out

• Trailing operating margin is -63.7% and net margin is -82.7%, far worse than the 2025 full-year operating margin of -28.5%.
• Annual revenue was roughly flat in 2025 (-0.5%) after a 23.6% drop in 2024.
• Shares closed at ₩2,035 on 19 October 2026, with a market cap of ₩28.3B, down 11.5% over one year and near the middle of a 52-week range of ₩1,341 to ₩2,890.
• Price-to-book is 2.5 and price-to-sales is 4.5, while P/E is not meaningful because earnings are negative; the data pack does not include analyst ratings or price targets.
• Recent filings are mostly routine: a half-year report, shareholder meeting results, shareholding reports and investor relations events. Net foreign ownership is 0.5% and unchanged over 60 days.

What to watch

• The next quarterly or annual results, to see whether revenue stabilises and losses narrow from the current trailing figures.
• Cash burn: free cash flow was about -₩2.4B on a trailing basis against ₩6.4B of cash, so future funding needs are worth monitoring.
• The company is exploring cosmetics and microbiome businesses, and a filing mentioned a change to its business purpose; the data does not say how material these moves are. No recent news headlines are included in the data.